Longevity / NMN Long-Term Safety: What 10 Years of Research Shows

NMN Long-Term Safety: What 10 Years of Research Shows

Written by

Sophie Chabloz

Anyone considering a daily supplement they plan to take for years deserves a clear answer about long-term safety. NMN has been studied in humans since 2020, when the first clinical safety study was published, building on animal work that goes back further. This piece sets out what the safety data shows, where the gaps are, who should be cautious, and how AVEA thinks about the question of multi-year use.

In this article:

The published safety record at 2026
Tolerability across the major trials
Long-term observational data and what’s missing
Theoretical concerns and how to think about them
Who should be cautious about NMN
AVEA’s quality controls and post-market monitoring
Where to go next

The published safety record at 2026

NMN has been studied in humans across roughly a dozen randomised controlled trials, with doses ranging from 100 mg to 1,250 mg per day and durations that mostly run from 4 to 12 weeks. The aggregate short-term safety record is reassuring.

No trial to date has reported a serious adverse event attributable to NMN at the doses tested. Mild gastrointestinal symptoms (occasional nausea, mild stomach discomfort) have been reported at low rates, typically under 5 percent of participants and generally no different from placebo. No trial has reported liver enzyme abnormalities, kidney function changes, or cardiovascular events linked to NMN exposure.

Animal studies extend the picture backwards in time. In the landmark long-term study, 12 months of NMN administration in mice was well-tolerated, with no signs of toxicity and no increase in tumour formation (Mills et al., 2016).

This is a strong short-term record by supplement standards. Many widely used supplements with longer histories (high-dose vitamin E, certain herbal extracts) have less reassuring data behind them.

Tolerability across the major trials

The pattern of side effects across NMN trials is consistent.

Irie et al. 2020 (single oral doses up to 500 mg in healthy men): no significant clinical changes or adverse events.

Yoshino et al. 2021 (250 mg per day for 10 weeks in postmenopausal women with prediabetes): no significant adverse events; one participant withdrew for unrelated reasons.

Pencina et al. 2023 (300, 600, and 900 mg per day for 60 days in adults): no dose-dependent adverse events; mild gastrointestinal complaints at low rates across all groups, including placebo.

Liao et al. 2021 (300 mg per day and higher for 6 weeks in amateur runners): no significant adverse events.

A separate 2022 trial found that 1,250 mg per day for 4 weeks was well-tolerated in healthy adults, with no severe adverse events, which covers the upper end of the doses people actually use.

Across these and other trials, the consistent pattern is that NMN is well-tolerated at the doses and durations studied.

Long-term observational data and what’s missing

The clear gap in the evidence base is that no published trial has followed NMN users for more than a few months. This isn’t unusual for newer supplements. Most supplement trials run 8 to 24 weeks, because that’s when efficacy signals appear most clearly, and longer trials are expensive and harder to enrol.

What we have instead is observational data from real-world use. AVEA has been selling NMN since 2021, with thousands of customers maintaining daily use for two to four years now. We monitor adverse event reports through customer service, and the rate of reported issues is consistent with what trials have shown: low frequency, mild severity, mostly gastrointestinal and self-resolving.

The longer-term population-level data we’d ideally have (decade-long cohort studies of NMN users) doesn’t yet exist in published form. This is the single biggest gap in the safety picture, and it’s worth being honest about rather than papering over.

Theoretical concerns and how to think about them

A few theoretical concerns come up in scientific discussions of NMN. They’re worth addressing directly.

The cancer concern. NAD+ supports cellular processes, including some that cancer cells depend on, and some researchers have argued that raising NAD+ could in theory support tumour growth. The counterargument is that NAD+ also supports DNA repair and immune surveillance, both of which protect against cancer. Animal data has not shown an increased cancer signal from NMN supplementation, and in humans the trials are too short to detect long-term cancer outcomes either way. The reasonable position: if you have an active cancer diagnosis, discuss NMN with your oncologist before continuing. For healthy adults, the concern remains theoretical and is not currently supported by evidence.

The methylation concern. NMN ultimately produces nicotinamide as a clearance by-product, and nicotinamide is metabolised through methylation pathways that consume methyl groups. In theory, sustained high-dose NMN could draw down methyl donor reserves. In practice, at doses of 250-500 mg per day the methylation demand is modest and easily met by adequate folate, B12, and choline intake. Some protocols pair NMN with TMG (trimethylglycine) for extra methyl support, which is reasonable at higher doses.

The CD38 feedback concern. CD38 expression is induced by inflammatory signalling, and some animal models suggest elevated NAD+ could modestly upregulate CD38 as a compensatory response. The clinical significance of this in humans is unclear and not currently a demonstrated real-world concern.

Who should be cautious about NMN

Specific situations where extra caution is warranted:

Active cancer treatment or recent cancer history. Discuss with your oncologist before starting or continuing NMN.

Pregnancy or breastfeeding. NMN has not been adequately studied in pregnant or nursing women. The default for any supplement in this group is to pause unless a doctor advises otherwise.

Severe kidney or liver disease. Although NMN is well-tolerated in healthy adults, anyone with significant organ dysfunction should clear new supplements with their physician.

Medications with narrow therapeutic windows. NMN is not known to interact with most common medications, but anyone on warfarin, lithium, or chemotherapy agents should check before adding any new supplement.

Children and adolescents. NMN has been studied in adults. Use in younger people is not supported by current evidence and should be avoided absent specific medical guidance.

For healthy adults outside these categories, the safety profile of NMN at 250-500 mg per day is well-supported by the available short-term evidence.

AVEA’s quality controls and post-market monitoring

The biggest practical risk in long-term NMN use is product quality, not the molecule itself. A poorly manufactured NMN can contain heavy metals, residual solvents, or other contaminants that wouldn’t appear in a quality product but could cause real problems with chronic exposure.

AVEA’s quality controls address this directly. Every batch of Longevir NMN is independently tested in a Swiss laboratory before release. Tests include identity (HPLC confirmation), purity (greater than 99 percent verified), heavy metals (lead, mercury, cadmium, arsenic), microbiological contaminants, and residual solvents.

We also maintain post-market surveillance. Any reported adverse event is logged and reviewed, and any pattern that appears more than once is investigated. The customer service record across thousands of users over multiple years is consistent with the trial data: rare, mild, self-resolving issues, with no signal of serious harm.

Where to go next

If you’re trying to settle on a dose given the safety data, NMN dosage: 250 mg vs 500 mg vs higher amounts covers the dose-response evidence. To verify what you’re actually buying, How to choose a high-quality NMN supplement: purity, sourcing, third-party testing covers the quality framework. And “NAD+ Decline and How to Restore It” gives the broader context.